Pasithea Therapeutics Corp.
KTTA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KTTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KTTA
Pasithea Therapeutics Corp. is a pre-revenue biotech company focused on developing novel therapies for central nervous system disorders and other diseases, currently advancing preclinical and clinical-stage candidates.
Key risk: Pre-revenue and no approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Pasithea Therapeutics Corp..
Pasithea Therapeutics Corp. is a pre-revenue biotech company focused on developing novel therapies for central nervous system disorders and other diseases, currently advancing preclinical and clinical-stage candidates.
- Cash and equivalents of $45.8M as of 2026-06-30 [sec].
- Net income of -$5.3M as of 2026-06-30 [sec].
- Shareholders' equity of $15.2M as of 2026-06-30 [sec].
- Management believes current cash will fund operations for at least the next twelve months as of 2026-08-14 [sec_mda].
- Company has no credit facility or committed sources of capital [sec_mda].
What works
- Cash position of $45.8M provides a runway for near-term operations as of 2026-06-30 [sec].
- Management states current cash is sufficient for at least the next twelve months as of 2026-08-14 [sec_mda].
What to weigh
- Company is pre-revenue with no approved products and expects to need significant additional funds for clinical trials and R&D [sec_mda].
- No credit facility or committed capital sources, creating financing uncertainty [sec_mda].
- Net loss of $5.3M in the latest quarter as of 2026-06-30 indicates ongoing cash burn [sec].
- Forward-looking statements are subject to numerous risks and uncertainties, including clinical trial outcomes and regulatory timelines [sec].
From the filings
Quoted directly from source documents.
Management believes current cash will fund operations for at least the next twelve months as of 2026-08-14
“We believe that our current available cash and cash equivalents will be sufficient to meet our working capital needs for at least the next twelve months and beyond.”
SEC MD&A · August 14, 2026
Company has no credit facility or committed sources of capital
“We currently have no credit facility or committed sources of capital.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue and no approved products — Company has no marketed products and expects to need significant additional funds for clinical trials and R&D [sec_mda].
- No committed capital sources — No credit facility or committed capital sources, creating financing risk [sec_mda].
- Clinical and regulatory uncertainties — Forward-looking statements subject to risks including clinical trial outcomes and regulatory timelines [sec].
- Net loss and cash burn — Net loss of $5.3M in latest quarter as of 2026-06-30 indicates ongoing cash consumption [sec].
What to watch
- Progress of preclinical and clinical development programs [sec_mda].
- Any future financing events or capital raises [sec_mda].
- Regulatory milestones and clinical trial data readouts [sec_mda].
- Changes in cash position and burn rate [sec].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Pasithea Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pasithea Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
29.6 months
D/E 0.04 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$6.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,200,000 | $3.1M |
| adage capital partners gp, l.l.c. | 2,100,000 | $1.6M |
| ameriprise financial inc | 1,350,896 | $1.0M |
| advisorshares investments llc | 337,508 | $250K |
| vanguard capital management llc | 107,630 | $80K |
| geode capital management, llc | 103,985 | $77K |
| renaissance technologies llc | 93,399 | $69K |
| vanguard fiduciary trust co | 43,860 | $33K |
| xtx topco ltd | 33,751 | $25K |
| ubs group ag | 26,149 | $19K |
Showing top 10 of 16 institutional holders of Pasithea Therapeutics Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.1%
- Days to cover
- 0.3
- Shares short
- 267,043
- Daily short volume (Jun 29, 2026)
- 42.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KTTA short interestFrequently asked questions
What is the AI investment thesis for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. is a pre-revenue biotech company focused on developing novel therapies for central nervous system disorders and other diseases, currently advancing preclinical and clinical-stage candidates.
What is Pasithea Therapeutics Corp.'s lead drug candidate?
Pasithea Therapeutics Corp.'s most advanced tracked candidate is pas-004 (Phase 1) for RAS Mutation; NF1 Mutation.
Who is the CEO of Pasithea Therapeutics Corp.?
Dr. Tiago Reis Marques M.D., Ph.D. is the chief executive officer of Pasithea Therapeutics Corp. (KTTA).
Where is Pasithea Therapeutics Corp. headquartered?
Pasithea Therapeutics Corp. (KTTA) is headquartered in Miami Beach, FL, United States.
What therapeutic areas does Pasithea Therapeutics Corp. focus on?
Pasithea Therapeutics Corp. develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.